Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2003
06/05/2003US20030105028 Substituted 2-azetidinones useful as hypocholesterolemic agents
06/05/2003US20030105027 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
06/05/2003US20030105024 Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
06/05/2003US20030104996 L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
06/05/2003US20030104977 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
06/05/2003US20030104975 Useful for identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/ or SRCs cofactors (Translation initiation factor-2 and steroid receptor cofactors)
06/05/2003US20030104974 Dual inhibitorsof PDE 7 and PDE 4
06/05/2003US20030104970 Modulating the growth state of an epithelial cell by ectopically contacting the epithelial cell, in vitro or in vivo, with hedgehog polypeptide or patched therapeutic to promote or inhibit of proliferation of epithelial cell
06/05/2003US20030104579 Pluripotent stem cells; antitumor agents; antiproliferative agents; antiinflammatory agents; veterinary medicine; tissue engineering
06/05/2003US20030104569 Proteins suppressing proliferation of lympho-hematopoietic cells
06/05/2003US20030104528 Lymphocytes; transcription factors; interferons
06/05/2003US20030104523 Process for high throughput screening of CpG-based immuno-agonist/antagonist
06/05/2003US20030104500 Enzymatic assays for screening anti-cancer agents
06/05/2003US20030104482 Death associated kinase containing ankyrin repeats (DAKAR)
06/05/2003US20030104478 Screening modulators of g-protein activity: for use in treatment of nervous system disorders
06/05/2003US20030104455 Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
06/05/2003US20030104450 Novel regulator of g protein signalling
06/05/2003US20030104419 Method of classifying a thyroid carcinoma using differential gene expression
06/05/2003US20030104399 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of body weight and aging disorders
06/05/2003US20030104377 Tenascin-C nucleic acid ligands
06/05/2003US20030104358 Polynucleotides for use in the detection of obesity, cancer, stroke, atherosclerosis, osteoarthritis, diabetes, asthma and autoimmune diseases
06/05/2003US20030104091 Probiotic formulation and method for reduction of pathogenic bacteria
06/05/2003US20030104088 Sulfated proteoglycan; one or more of a hexosamine sulfate,a flavone, olive kernel extract, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of CRH, caffeine, and a polyamine.
06/05/2003US20030104087 Proteoglycan compositions for treating arthritic inflammatory conditions
06/05/2003US20030104082 Microbe inhibitors comprising antimicrobial isolates, botanical extracts or phytochemicals; also Commiphora myrrha, Commiphora molmol, Commiphora erythraea, sequiterpenes, nutrient, a vitamin, or a vitamin B complex.
06/05/2003US20030104073 Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same
06/05/2003US20030104055 Antibiotic product, use and formulation thereof
06/05/2003US20030104045 Novel therapeutic binding molecule complexes
06/05/2003US20030104033 Contain caseinate and another protein, preferably soybean protein or whey; reduced rate of creaming and an enhanced shelf life.
06/05/2003US20030104016 Reducing inflammation by topically applying totarol or an ester of totarol
06/05/2003US20030104013 Inhibitor of histamine synthesis, especially of of histidine decarboxylase such as tritoqualine; allergen, e.g., cysteine protease
06/05/2003US20030103998 Treatment of HIV and other viral infections using combinatorial therapy
06/05/2003US20030103983 Ace inhibitor-vasopressin antagonist combinations
06/05/2003US20030103978 Antibodies and antigen binding domains used to prevent or treat conditions relating to loss of bone mass and bone disorders; nucleic acid encoding antibodies and antigen binding domains
06/05/2003US20030103974 Administering an antibodies or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss
06/05/2003US20030103973 Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy
06/05/2003US20030103969 Therapeutic treatment using an anti-CD14 antibody
06/05/2003US20030103955 For topical application; high penetration through skin; antiinflammatory agents
06/05/2003US20030103954 Comprises vitamin D3 for regulating cell differentiation and/or cell proliferation
06/05/2003US20030103953 Comprises vitamin D3 for controlling cell differentiation and/or cell proliferation
06/05/2003US20030103942 Comprises recombinant adeno-associated virus vectors encoding TNF antagonist; antiinflammatory agents for connective tissues and joints
06/05/2003US20030103936 Method of ex-vivo expansion of hematopoeitic cells using interleukin-3 (IL-3) multiple mutation polypeptides
06/05/2003CA2837936A1 Peptidomimetic inhibitors of post-proline cleaving enzymes
06/05/2003CA2468706A1 Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
06/05/2003CA2468511A1 A method for combined sequential agent delivery and electroporation for cell structures and use thereof
06/05/2003CA2468494A1 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
06/05/2003CA2468424A1 A method for combined parallel agent delivery and electroporation for cell structures and use thereof
06/05/2003CA2468408A1 Human cdnas and proteins and uses thereof
06/05/2003CA2468400A1 Antibiotics ge 81112 factors a, b, b1, pharmaceutically acceptable salts and compositions, and use thereof
06/05/2003CA2468390A1 Treatment of wounds and compositions employed
06/05/2003CA2468344A1 Methods and compositions for treating lesions of the respiratory epithelium
06/05/2003CA2468320A1 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
06/05/2003CA2468316A1 Novel compositions and methods for cancer
06/05/2003CA2468256A1 Compositions comprising phenyl-glycine derivatives
06/05/2003CA2468253A1 Process for coating a surface of a stent
06/05/2003CA2468246A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue
06/05/2003CA2468240A1 Muscle transcription factors
06/05/2003CA2468192A1 Peptidomimetic inhibitors of post-proline cleaving enzymes
06/05/2003CA2468131A1 Disruption of the prostaglandin e synthase 2 gene
06/05/2003CA2467677A1 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
06/05/2003CA2467647A1 Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
06/05/2003CA2467581A1 Milk protein biofilm and uses thereof
06/05/2003CA2467451A1 Method for controlling angiogenesis in animals
06/05/2003CA2467165A1 Therapeutic compounds for treating dyslipidemic conditions
06/05/2003CA2466867A1 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003CA2465846A1 Targeted therapeutics and uses thereof
06/05/2003CA2465072A1 Treatment of micro-organism infection
06/04/2003EP1316609A1 Acetoacetyl-CoA thiolase and its use for identifying new fungicidal substances
06/04/2003EP1316560A1 Novel human cancer/testis antigen and gene thereof
06/04/2003EP1316317A1 Hydrosoluble mixtures of cyproterone and/or an ester of it, processes to obtain them and uses thereof
06/04/2003EP1316313A2 Composition for the treatment of ischemic stroke containing zonampanel and a tissue plasminogen activator
06/04/2003EP1316311A1 Therapeutic use on-demand of formoterol and budesonide
06/04/2003EP1316310A1 Ophthalmic composition comprising a histidine derivative for healing asthenopia
06/04/2003EP1316308A1 Transdermal therapeutic device with capsaicin and capsaicin analogs
06/04/2003EP1316306A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316305A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316304A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316303A1 Cosmetic and/or dermatological use of a composition containing at least one oxidation-sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316302A1 Cosmetic and/or dermatological composition containing at least one oxidation sensitive hydrophilic active stabilised by at least one polymer or copolymer of N-vinylimidazole
06/04/2003EP1316203A2 Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
06/04/2003EP1315965A2 Methods and compositions for in vitro targeting
06/04/2003EP1315963A1 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
06/04/2003EP1315840A2 Biopanning and rapid analysis of selective interactive ligands (brasil)
06/04/2003EP1315837A2 5-hydroxytryptamine receptor gene polymorphisms and response to treatment
06/04/2003EP1315831A2 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
06/04/2003EP1315830A2 Compositions and methods for targeting peptides in humans in vivo
06/04/2003EP1315813A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/04/2003EP1315812A2 Modified polypeptides stabilized in a desired conformation and methods for producing same
06/04/2003EP1315800A2 Human proteases
06/04/2003EP1315793A1 Methods for culturing human lung mast cells and uses thereof
06/04/2003EP1315755A1 Anti-angiogenic peptides
06/04/2003EP1315754A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/04/2003EP1315753A2 Isolated human ion channel proteins, nucleic acid molecules encoding them, and uses thereof
06/04/2003EP1315751A2 Two receptors of meiosis activating sterols designated sam1a and sam1b
06/04/2003EP1315741A2 A method for treating allergies
06/04/2003EP1315719A1 Multivalent neuraminidase inhibitor conjugates
06/04/2003EP1315690A2 Generation of combinatorial libraries and assessment thereof by deconvolution
06/04/2003EP1315516A2 Modulation of beta-amyloid levels by beta-secretase bace2
06/04/2003EP1315514A2 Methods and compositions for producing a neurosalutary effect in a subject
06/04/2003EP1315512A2 Adenoviral targeting and manipulation of immune system response using targeting peptides
1 ... 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 ... 1151